Quarterly ResultMay 5, 2026, 07:08 AM
Pfizer Q1 Revenue $14.5B, +2% Op Growth; Reaffirms 2026 Guidance
AI Summary
Pfizer reported Q1 2026 revenues of $14.5 billion, an operational increase of 2% year-over-year, or 7% excluding COVID-19 products. Launched and acquired products saw 22% operational revenue growth. The company reaffirmed its full-year 2026 financial guidance, including revenues of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00. Key product developments and a strategic commercialization collaboration in China were also highlighted.
Key Highlights
- Q1 2026 Revenues totaled $14.5 billion, a 2% operational increase year-over-year.
- Revenues excluding Comirnaty and Paxlovid grew 7% operationally in Q1 2026.
- Launched and Acquired Products revenue grew 22% operationally in Q1 2026.
- Reported Diluted EPS was $0.47, and Adjusted Diluted EPS was $0.75 for Q1 2026.
- Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion.
- Full-year 2026 Adjusted Diluted EPS guidance reaffirmed at $2.80 to $3.00.
- Invested $2.5 billion in R&D and returned $2.4 billion in cash dividends in Q1 2026.
- Vyndamax patent settlements extended U.S. expiry to June 1, 2031, stabilizing revenues.